Is TL-99 a selective presynaptic dopamine receptor agonist?

Area of Science:

• Neuropharmacology
• Dopamine receptor research
• Adrenergic receptor research

Background:

• The compound TL-99, a 2-aminotetralin analogue, was proposed as a selective presynaptic dopamine (DA) receptor agonist.
• Understanding the precise receptor interactions of neuroactive compounds is crucial for drug development and therapeutic applications.

Purpose of the Study:

• To investigate the selectivity of TL-99 as a presynaptic dopamine receptor agonist.
• To elucidate the pharmacological mechanisms underlying the hypomotility induced by TL-99.
• To determine the effects of TL-99 on dopamine and noradrenaline metabolism and turnover in the rat brain.

Main Methods:

• In vivo studies in rats, including administration of TL-99 and selective antagonists.
• Assessment of hypomotility, dopamine metabolism, and neurotransmitter turnover using the alpha-methyl-p-tyrosine (alpha-MT) method.
• In vitro studies using striatal and cortical slices to measure the release of radiolabeled neurotransmitters (dopamine, acetylcholine, noradrenaline).

Main Results:

• In vivo and in vitro studies demonstrated that TL-99 activates both presynaptic dopamine receptors and noradrenaline (NA) receptors.
• Hypomotility induced by TL-99 was partially reversed by selective alpha 2-adrenoceptor antagonists (yohimbine, piperoxan).
• TL-99 inhibited the release of dopamine, acetylcholine, and noradrenaline from brain slices, indicating activity at pre- and postsynaptic DA receptors and alpha 2-NA receptors.

Conclusions:

• TL-99 exhibits potent agonist activity at alpha 2-noradrenaline receptors, comparable to clonidine.
• The hypomotility observed with TL-99 is likely due to its combined action on dopamine and noradrenaline receptors.
• TL-99 should not be classified as a selective presynaptic dopamine receptor agonist due to its significant adrenergic activity.